MARKET

ANIK

ANIK

Anika
NASDAQ

Real-time Quotes | Nasdaq Last Sale

33.54
+0.20
+0.60%
Closed 16:04 10/29 EDT
OPEN
33.21
PREV CLOSE
33.34
HIGH
34.00
LOW
32.85
VOLUME
73.46K
TURNOVER
--
52 WEEK HIGH
71.05
52 WEEK LOW
22.01
MARKET CAP
476.52M
P/E (TTM)
43.23
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Anika to Issue Third Quarter 2020 Financial Results and Business Highlights on Wednesday, November 4, 2020
BEDFORD, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care, today announced that the Company plans to issue its third quarter 2020 financial results after the close of the market on Wednesday, November 4, 2020 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights. The conference call can be accessed by dialing 1-855-327-6837 (toll-free domestic) or 1-631-891-4304 (international) and providing the conference ID number 10011177. A live audio webcast will be available in the "Investor Relations" section of Anika's website, www.anika.com. An accompanying slide presentation also can be accessed via the Anika website. The call will be archived and accessible on the same website shortly after its conclusion.About Anika Therapeutics, Inc.Anika Therapeutics, Inc. (NASDAQ: ANIK), is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. We partner with physicians to understand what they need most to treat their patients and we develop minimally invasive products that restore active living for people around the world. We are committed to leading in high opportunity spaces within orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair and bone preserving joint technologies. For more information, please visit www.anika.com.For Investor Inquiries: Anika Therapeutics, Inc. Kristen Galfetti, 781-457-9000 Executive Director, Investor Relations investorrelations@anika.com For Media Inquiries: W2O Group Rachel Girard, 617-379-6760 rgirard@w2ogroup.com
GlobeNewswire · 10/22 21:05
FDA OKs Anika wrist restoration device
The FDA grants 510(k) clearance to Anika Therapeutics' (ANIK) WristMotion Total Arthroplasty System for the replacement of the wrist joint due to rheumatoid arthritis, osteoarthritis, or post-traumatic arthritis.The event triggers
Seekingalpha · 10/21 20:13
Anika Announces FDA 510(k) Clearance For Its WristMotion Total Arthroplasty System For The Replacement Of Painful Wrist Joints
BEDFORD, Mass., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic
Benzinga · 10/21 20:10
Anika Announces FDA 510(k) Clearance for its WristMotion® Total Arthroplasty System for the Replacement of Painful Wrist Joints
Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care, today announced that the Company’s WristMotion
Benzinga · 10/21 20:09
Analysts Estimate Anika Therapeutics (ANIK) to Report a Decline in Earnings: What to Look Out for
Anika (ANIK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 10/15 17:31
Anika Announces Appointment of Jack Henneman and Stephen Richard to Board of Directors
Board Chair Joseph Bower, D.B.A. announces intention not to stand for re-election at 2021 Annual Meeting Jeffery Thompson succeeds Dr. Bower as Chair of the BoardBEDFORD, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation, restoration
GlobeNewswire · 09/08 21:53
ANIK vs. NEO: Which Stock Is the Better Value Option?
ANIK vs. NEO: Which Stock Is the Better Value Option?
Zacks · 09/07 16:40
Anika to Participate in Upcoming Virtual Investor Conferences
BEDFORD, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation, restoration and regenerative solutions company with products across the orthopedic early intervention continuum of care, today announced that Cheryl R. Blanchard, Ph.D.
GlobeNewswire · 09/03 19:34
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ANIK. Analyze the recent business situations of Anika through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ANIK stock price target is 51.00 with a high estimate of 51.00 and a low estimate of 51.00.
EPS
Institutional Holdings
Institutions: 263
Institutional Holdings: 15.30M
% Owned: 107.71%
Shares Outstanding: 14.21M
TypeInstitutionsShares
Increased
54
1.33M
New
39
55.60K
Decreased
60
573.66K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.19%
Pharmaceuticals & Medical Research
+0.17%
Key Executives
Chairman/Independent Director
Joseph Bower
President/Chief Executive Officer/Director
Cheryl Blanchard
Chief Financial Officer/Executive Vice President/Treasurer
Michael Levitz
Executive Vice President/General Counsel/Secretary
David Colleran
Executive Vice President/Director of Human Resources
Thomas Finnerty
Executive Vice President
James Loerop
Independent Director
John Henneman
Independent Director
Raymond Land
Independent Director
Jeffrey Thompson
Independent Director
Glenn Larsen
Independent Director
Stephen Richard
Independent Director
Jeffery Thompson
Independent Director
Susan Vogt
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ANIK
Anika Therapeutics, Inc. is a joint preservation company. The Company creates and delivers advancements in early intervention orthopedic care. It partners with physicians and develops minimally invasive products. It focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair and bone preserving joint technologies. Its product categories include joint pain management therapies, orthopedic joint preservation and restoration care, and other. The joint pain management therapies offer injectable viscosupplement products that provide pain relief from osteoarthritis conditions and its products include MONOVISC, ORTHOVISC, CINGAL and HYVISC. The Company's orthopedic joint preservation and restoration care products include HYALOFAST and TACTOSET. It also offers a line of surgical implant and instrumentation solutions that are used by surgeons to repair and reconstruct damaged ligaments and tendons due to sports injuries, trauma and disease.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Anika Therapeutics Inc stock information, including NASDAQ:ANIK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ANIK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ANIK stock methods without spending real money on the virtual paper trading platform.